Marjorie Pick
Overview
Explore the profile of Marjorie Pick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lebel E, Asherie N, Kfir-Erenfeld S, Grisariu S, Avni B, Elias S, et al.
J Clin Oncol
. 2024 Dec;
:JCO2402252.
PMID: 39653116
Purpose: The use of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA CART was the first...
2.
Kfir-Erenfeld S, Asherie N, Lebel E, Vainstein V, Assayag M, Dubnikov Sharon T, et al.
Blood Adv
. 2024 May;
8(15):4077-4088.
PMID: 38768428
HBI0101 is an academic chimeric antigen receptor T-cell (CART)-targeted to B-cell maturation antigen (BCMA) for the treatment of relapsed and refractory multiple myeloma (R/RMM) and light chain amyloidosis. Herein, we...
3.
Pick M, Lebel E, Elgavish S, Benyamini H, Nevo Y, Hertz R, et al.
Haematologica
. 2023 Jun;
108(12):3359-3371.
PMID: 37381778
Systemic light chain amyloidosis (AL) is a clonal plasma cell disorder characterized by the deposition of misfolded immunoglobulin light chains (LC) as insoluble fibrils in organs. The lack of suitable...
4.
Asherie N, Kfir-Erenfeld S, Avni B, Assayag M, Dubnikov T, Zalcman N, et al.
Haematologica
. 2022 Oct;
108(7):1827-1839.
PMID: 36200421
Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy shows remarkable efficacy in patients with relapsed and/or refractory (R/R) multiple myeloma (MM). HBI0101, a novel second generation optimized...
5.
Kfir-Erenfeld S, Asherie N, Grisariu S, Avni B, Zimran E, Assayag M, et al.
Clin Cancer Res
. 2022 Sep;
28(23):5156-5166.
PMID: 36107221
Purpose: AL amyloidosis (AL) treatments are generally based on those employed for multiple myeloma. Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T (CART)-cell therapy, already approved for multiple myeloma, might...
6.
Even-Zohar N, Pick M, Hofstetter L, Shaulov A, Nachmias B, Lebel E, et al.
J Clin Med
. 2022 May;
11(10).
PMID: 35629039
Surface antigens are commonly used in flow cytometry assays for the diagnosis of multiple myeloma (MM). Some of these are directly involved in MM pathogenesis or interactions with the microenvironment,...
7.
Lebel E, Nachmias B, Pick M, Even-Zohar N, Gatt M
J Clin Med
. 2022 Apr;
11(7).
PMID: 35407416
Multiple myeloma (MM) progression is dependent on its interaction with the bone marrow microenvironment and the immune system and is mediated by key surface antigens. Some antigens promote adhesion to...
8.
Serum Hevylite assay in the differential diagnosis of patients with high suspicion of AL Amyloidosis
Yogev D, Pick M, Slyusarevsky E, Pogrebijski G, Pickin A, Gatt M
Int J Lab Hematol
. 2021 Jan;
43(3):418-425.
PMID: 33455086
Introduction: AL amyloidosis (AL) is a malignant form of plasma cell dyscrasia (PCD). It is insidious, and its end-organ damage can mimic that of common diseases. At diagnosis, routine tests...
9.
Gilad N, Zukerman H, Pick M, Gatt M
Oncotarget
. 2019 Sep;
10(52):5480-5491.
PMID: 31534632
Multiple myeloma (MM) is an incurable neoplasm characterized by infiltration of malignant plasma cells (PCs). Recently, the tumor microenvironment has become of great interest in MM as it known to...
10.
Pick M, Vainstein V, Goldschmidt N, Lavie D, Libster D, Gural A, et al.
Eur J Haematol
. 2018 Feb;
100(5):494-501.
PMID: 29453884
Objective: Daratumumab is a promising new antimyeloma agent. We report a single center "real-world" series of multiple myeloma (MM) and amyloidosis (AL) patients treated with daratumumab. Methods: Forty-one patients were...